Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01502670 · ClinicalTrials.gov registry record · Phase 1
Amino Acid Tracer (FACBC) Positron Emission Tomography for Lung Nodule
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01502670 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 10 participants.
The verdict
NCT01502670, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will look at how the \[18\]FACBC goes into the lung nodules. This will hopefully lead to the development of better imaging techniques to look at lung nodules. \[18\]FACBC is not approved by the FDA (Food and Drug Administration). This study will help to determine if it should be approved by the FDA.
Interventions
- DRUG 18F-FACBC Radiotracer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-05 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01502670
The ClinicalTrials.gov registry entry for NCT01502670 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 18F-FACBC Radiotracer is the first listed.
NCT01502670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01502670 about?
NCT01502670 is a clinical study titled "Amino Acid Tracer (FACBC) Positron Emission Tomography for Lung Nodule". This study will look at how the \[18\]FACBC goes into the lung nodules. This will hopefully lead to the development of better imaging techniques to look at lung nodules. \[18\]FACBC is not approved by the FDA (Food and Drug Administration). This study will help to determine if it should be approved ...
What is the current status of trial NCT01502670?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2009-05. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01502670?
The interventions under investigation include: 18F-FACBC Radiotracer (DRUG).
Who is sponsoring clinical trial NCT01502670?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.